Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$116.17 USD
+0.71 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $116.20 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$116.17 USD
+0.71 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $116.20 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at Diagnostics segment.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by net dialysis and the related lab patient service segment are likely to have aided DaVita's (DVA) top line in the first quarter.
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect strength in the Global Healthcare and Life Sciences segment.
Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus
by Debanjana Dey
Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.
Zimmer Biomet (ZBH) Enhances ZBEdge Portfolio With Latest Suite
by Zacks Equity Research
Zimmer Biomet's (ZBH) latest portfolio enhancement is aimed at improving patient outcome throughout the entire treatment process.
Zimmer Biomet (ZBH) Shows Strong Core Growth Amid Weak EMEA
by Zacks Equity Research
For Zimmer Biomet (ZBH), the spin-off is an important step forward to its transition into a more streamlined business with a focus on more optimized resource allocation.
Why Is Zimmer (ZBH) Down 1.4% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer (ZBH) Non-Core Arm Spinoff to Aid Amid COVID-19 Crisis
by Zacks Equity Research
In the Americas, there is increased pressure on Zimmer Biomet (ZBH) procedural volume as a result of surge in infections.
Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio
by Zacks Equity Research
Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 2.43% and 0.57%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) patient volumes are expected to have increased significantly in the fourth quarter due to pent-up demand.
Zimmer Biomet (ZBH) Shows Strong APAC Recovery, EMEA Slow
by Zacks Equity Research
Zimmer Biomet (ZBH) is performing well in its priority areas like quality remediation, supply recovery efforts and product introductions.
Zimmer Biomet (ZBH) Shows Strong Recovery Amid COVID-19 Woes
by Zacks Equity Research
Owing to lack of clarity around the scope and duration of the coronavirus pandemic, Zimmer Biomet (ZBH) is unable to gauge the impact on its overall business in 2020.
Zimmer Biomet (ZBH), HSS Partner to Advance Remote Patient Care
by Zacks Equity Research
Zimmer Biomet's (ZBH) mymobility with Apple Watch platform aids in transforming virtual patient care via the latest partnership with HSS.
Should Value Investors Now Choose Zimmer Biomet (ZBH) Stock?
by Zacks Equity Research
Let's see if Zimmer Biomet (ZBH) stock is a good choice for value-oriented investors right now from multiple angles.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement in the third quarter.
Zimmer (ZBH) Up 7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer Biomet (ZBH) Boosts Portfolio With A&E Medical Buyout
by Zacks Equity Research
This latest development aligns with Zimmer Biomet's (ZBH) active portfolio management strategy and the ongoing transformation of business aimed at long-term growth.
Globus Medical (GMED) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Globus Medical (GMED) is optimistic about maintaining robust product portfolio along with strength in its domestic spine business.